Skandinaviska Enskilda Banken AB publ Has $7.74 Million Stock Position in BridgeBio Pharma, Inc. $BBIO

Skandinaviska Enskilda Banken AB publ lifted its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 152.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 148,917 shares of the company’s stock after purchasing an additional 89,856 shares during the period. Skandinaviska Enskilda Banken AB publ owned 0.08% of BridgeBio Pharma worth $7,735,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of BBIO. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of BridgeBio Pharma in the 2nd quarter valued at about $25,000. Jones Financial Companies Lllp acquired a new stake in BridgeBio Pharma during the 1st quarter valued at approximately $35,000. First Horizon Corp acquired a new stake in BridgeBio Pharma during the 3rd quarter valued at approximately $36,000. AlphaQuest LLC raised its holdings in BridgeBio Pharma by 254.3% during the 3rd quarter. AlphaQuest LLC now owns 815 shares of the company’s stock worth $42,000 after purchasing an additional 585 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of BridgeBio Pharma by 28.6% in the 3rd quarter. GAMMA Investing LLC now owns 1,020 shares of the company’s stock worth $53,000 after purchasing an additional 227 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Phase 3 PROPEL‑3 achondroplasia results improve the program’s regulatory and commercial outlook — a clear fundamental catalyst supporting upside for BBIO. Read More.
• Positive Sentiment: HC Wainwright raised near‑term EPS estimates and bumped its price target to $100 while keeping a Buy rating — analyst upgrades can lift sentiment and buying interest. Read More.
• Neutral Sentiment: Upcoming Q4/2025 earnings and Feb. 24 conference call create a scheduled event risk: results and program/cash‑burn details could drive short‑term volatility either way. Read More.
• Neutral Sentiment: Company granted inducement RSUs to new hires (76,701 shares) — modest ongoing dilution to monitor but not a large immediate overhang. Read More.
• Neutral Sentiment: Small institutional buying: Oppenheimer reported a new 7,845‑share stake per 13F filing — signals some investor interest but immaterial scale. Read More.
• Negative Sentiment: Clustered insider selling on Feb. 17: Director Randal Scott sold 10,000 shares (~$754k) and the CFO sold 13,600 shares (~$1.02M), alongside other officer sales — concentrated disposals are pressuring near‑term sentiment. Read More.
• Negative Sentiment: Smaller CAO sale (510 shares) and a pattern of executive liquidity events — repeated sales by insiders can keep downward pressure until management rebuilds conviction via buying or other signals. Read More.
• Neutral Sentiment: Reported short‑interest data is inconsistent (entries show zero shares / NaN) and does not currently indicate a material short‑squeeze dynamic — treat the short‑interest note as noise until clearer reporting emerges.

BridgeBio Pharma Trading Down 4.3%

BBIO opened at $70.72 on Friday. The company has a fifty day moving average price of $75.66 and a two-hundred day moving average price of $63.84. BridgeBio Pharma, Inc. has a 1-year low of $28.33 and a 1-year high of $84.94. The company has a market cap of $13.63 billion, a P/E ratio of -16.92 and a beta of 1.13.

Insider Transactions at BridgeBio Pharma

In related news, CEO Neil Kumar sold 40,000 shares of the stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $71.94, for a total value of $2,877,600.00. Following the transaction, the chief executive officer directly owned 695,686 shares in the company, valued at $50,047,650.84. This trade represents a 5.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Randal W. Scott sold 10,000 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $75.46, for a total transaction of $754,600.00. Following the sale, the director owned 11,589 shares of the company’s stock, valued at $874,505.94. This trade represents a 46.32% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 176,121 shares of company stock worth $13,009,631. Insiders own 18.20% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Piper Sandler increased their price objective on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the stock an “overweight” rating in a research report on Thursday, October 30th. Barclays started coverage on shares of BridgeBio Pharma in a research report on Wednesday, January 28th. They set an “overweight” rating on the stock. JPMorgan Chase & Co. increased their price target on BridgeBio Pharma from $76.00 to $77.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Morgan Stanley initiated coverage on BridgeBio Pharma in a research report on Tuesday, January 6th. They issued an “overweight” rating and a $96.00 price objective for the company. Finally, Cantor Fitzgerald upped their target price on BridgeBio Pharma from $100.00 to $110.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. Twenty-two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $82.05.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.